Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Jianxing ZhouYou ZhengBaohua XuSongjun LongLi-E ZhuYunhui LiuChengliang LiYifan ZhangMaobai LiuXuemei WuPublished in: BMC medicine (2024)
We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity.
Keyphrases
- adverse drug
- end stage renal disease
- ejection fraction
- newly diagnosed
- metabolic syndrome
- rheumatoid arthritis
- type diabetes
- insulin resistance
- depressive symptoms
- weight loss
- emergency department
- drug induced
- peritoneal dialysis
- palliative care
- weight gain
- body mass index
- systemic lupus erythematosus
- human health
- climate change
- patient reported outcomes
- ankylosing spondylitis
- skeletal muscle
- adipose tissue
- disease activity